TG Therapeutics Inc (TGTX)

NASDAQ
31.28
+0.65(+2.12%)
After Hours
31.00
-0.28(-0.90%)
- Real-time Data
  • Volume:
    2,786,284
  • Bid/Ask:
    31.00/31.15
  • Day's Range:
    29.93 - 31.41
  • Type:Equity
  • Market:United States
  • ISIN:US88322Q1085
  • CUSIP:00088322Q108

TGTX Overview

Prev. Close
30.63
Day's Range
29.93-31.41
Revenue
2.41M
Open
30.69
52 wk Range
21.06-56.62
EPS
-2.72
Volume
2,786,284
Market Cap
4.09B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,498,548
P/E Ratio
-
Beta
2.09
1-Year Change
19.62%
Shares Outstanding
130,721,777
Next Earnings Date
09 Nov 2021
What is your sentiment on TG Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

TG Therapeutics Inc News

TG Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuySell

TG Therapeutics Inc Company Profile

TG Therapeutics Inc Company Profile

Employees
328

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.